Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 3

From BugSigDB


Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10

Curated date: 2021/06/25

Curator: Claregrieve1

Revision editor(s): Claregrieve1, WikiWorks

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
COVID-19 2019 novel coronavirus,2019 novel coronavirus infection,2019-nCoV,2019-nCoV infection,beta-CoV,beta-CoVs,betacoronavirus,coronavirus disease 2019,SARS-coronavirus 2,SARS-CoV-2,severe acute respiratory syndrome coronavirus 2,severe acute respiratory syndrome coronavirus 2 infectious disease,β-coronavirus,β-CoV,β-CoVs,COVID-19,cOVID-19
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy controls
Group 1 name Corresponds to the case (exposed) group for case-control studies
COVID-19 patients
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Suspected COVID-19 cases with one of the following etiological or serological evidence: (1) Fluorescence RT-PCR detects the positive of the COVID-19 virus nucleic acid. (2) Viral gene sequencing finds highly homologous to COVID-19 virus
Group 0 sample size Number of subjects in the control (unexposed) group
48
Group 1 sample size Number of subjects in the case (exposed) group
24
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Receipt of antibiotics and/or probiotics within 8 weeks prior to enrollment

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V5
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
2

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
decreased

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10

Curated date: 2021/06/25

Curator: Claregrieve1

Revision editor(s): Lwaldron, Claregrieve1

Source: Figure 5c, S3E, S3G -Supp 05

Description: Differential microbial abundance between samples from healthy controls and samples from COVID-19 patients

Abundance in Group 1: decreased abundance in COVID-19 patients

NCBI Quality ControlLinks
Alistipes
Bacteroides
Bilophila
Blautia
Clostridium
Collinsella
Coprococcus
Dialister
Dorea
Faecalibacterium
Haemophilus
Holdemania
Intestinimonas
Klebsiella
Lachnospira
Odoribacter
Parabacteroides
Parasutterella
Pseudobutyrivibrio
Roseburia
Ruminococcus
Sphingomonas
Sutterella
Turicibacter
bacterium
uncultured Oscillospiraceae bacterium

Revision editor(s): Lwaldron, Claregrieve1

Signature 2

Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10

Curated date: 2021/06/25

Curator: Claregrieve1

Revision editor(s): Claregrieve1

Source: Figure 5c

Description: Differential microbial abundance between samples from healthy controls and samples from COVID-19 patients

Abundance in Group 1: increased abundance in COVID-19 patients

NCBI Quality ControlLinks
Akkermansia
Bifidobacterium
Enterococcus
Lachnospiraceae incertae sedis
Streptococcus
Rothia
Halomonas
Anaerostipes
Oribacterium
Veillonella
Solobacterium
Atopobium
Flavonifractor
Pelagibacterium
Gemella
Granulicatella

Revision editor(s): Claregrieve1